Lifecare AS’ Q4 2022 Report is now available. See attached document:
Bergen, Norway 11 may 2023
Today Lifecare publish Q1 2023 interim report.
The consolidated group financials show a revenue in Q1 of 2.61 MNOK, compared to 1,98 MNOK in Q1 2022, while the Operating result in Q1 2023 ended at -6.38 MNOK, up from -4,88 MNOK in Q1 2022 due to increase in company’s activities after reaching the clinical stage.
On the operational side the company can today disclose;
– Lifecare’s first Clinical Study has been successfully finalized (https://newsweb.oslobors.no/message/590329)
– Lifecare Laboratory achieved ISO 9001 certification with effect from April 17th, 2023
– Lifecare’s sensor continue to prove its robustness in combined in-vivo/in-vitro experiments
Further information: Joacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40